Mode
Text Size
Log in / Sign up

Rh five-antigen-matched transfusions associated with lower alloimmunization in patients needing repeated RBC transfusions

Rh five-antigen-matched transfusions associated with lower alloimmunization in patients needing repe…
Photo by Alexander Grey / Unsplash
Key Takeaway
Consider Rh five-antigen matching for high-risk transfusion patients, but note limited numerical data.

A randomized controlled trial investigated Rh five-antigen (D, C, c, E, e)–matched transfusions versus conventional antigen matching in patients requiring multiple red blood cell transfusions. The primary outcome was the incidence of RBC alloantibody formation. The study found a significantly lower incidence of alloantibody formation in the Rh five-antigen–matched group, though absolute numbers, effect sizes, and confidence intervals were not reported. Multivariable analyses were performed to adjust for potential confounders.

Secondary outcomes also favored the intervention. The Rh five-antigen–matched group had fewer transfusion-related adverse reactions, reduced RBC utilization, longer transfusion intervals, and shorter length of hospital stay. The direction of these associations was consistent, but specific numerical data for these outcomes were not provided in the abstract. Safety and tolerability details, including adverse events and discontinuations, were not reported.

Key limitations include the lack of reported sample size, follow-up duration, and specific numerical results for all outcomes. The funding source and potential conflicts of interest were also not reported. The abstract appropriately frames the findings as associations rather than proven causal effects. The authors note the long-term clinical value and cost-effectiveness should be further explored in multicenter studies.

For practice, this strategy represents a viable transfusion management approach for patients at high immunological risk. However, clinicians should interpret these preliminary findings with caution due to the absence of critical numerical data needed to fully assess the magnitude of benefit. Further research is needed to confirm these associations and establish practical implementation guidelines.

Study Details

Study typeRct
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
BackgroundRed blood cell (RBC) alloimmunization remains a significant challenge in patients requiring repeated transfusions, complicating transfusion procedures and increasing healthcare resource utilization. While extended Rh antigen matching has been proposed to mitigate alloimmunization, prospective data on its impact on transfusion-related outcomes and clinical management remain limited.MethodsIn this prospective, randomized controlled study, patients requiring multiple RBC transfusions were randomly assigned to receive either conventional antigen matching or Rh five-antigen (D, C, c, E, e)–matched transfusions. The primary endpoint was the incidence of RBC alloantibody formation. Secondary endpoints included transfusion-related adverse reactions, as well as transfusion management outcomes such as RBC utilization, transfusion intervals, and length of hospital stay. Multivariable analyses were performed to adjust for potential confounders.ResultsPatients in the Rh five-antigen–matched group demonstrated a significantly lower incidence of alloantibody formation and fewer transfusion-related adverse reactions compared to the conventional matching group. Additionally, Rh five-antigen matching was associated with reduced RBC utilization, longer transfusion intervals, and shorter hospital stays. After adjusting for relevant clinical variables, Rh five-antigen–matched transfusion remained independently associated with lower RBC utilization.ConclusionIn patients requiring repeated RBC transfusions, Rh five-antigen–matched transfusion was associated with a reduced risk of alloantibody formation and more favorable transfusion management outcomes. This strategy represents a viable transfusion management approach for patients at high immunological risk, and its long-term clinical value and cost-effectiveness should be further explored in multicenter studies.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.